The board of directors of healthcare technology company Medtronic plc (NYSE:MDT) authorised a dividend of USD0.63 per share of the company's ordinary stock for the Q3 fiscal year 2022, it disclosed on Friday.
In addition, the new cash dividend is up by 9% over the prior year and is consistent with the announcement made by the company in May 2021. It has increased its annual dividend payment for the past 44 consecutive years.
This upsized cash dividend will be paid on 14 January 2022 to shareholders of record at the close of business as of 22 December 2021.
Headquartered in Dublin, Ireland, Medtronic's technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems and more.
First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus
ARX788 Included in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
Roche first quarter sales up by 10% on strong demand for rapid COVID-19 antigen tests
STENTiT concludes EUR1.8m as part of seed investment round
Dr. Reddy's Laboratories Launches Posaconazole Delayed-Release Tablets in the US Market
Former ViaCyte CEO Paul Laikind Joins Stemson Therapeutics Board of Directors
Axol Bioscience Raises GBP 3.2m in Extension of Previous Funding Round